<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alpha-glucosidase inhibitors for treatment of diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alpha-glucosidase inhibitors for treatment of diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Alpha-glucosidase inhibitors for treatment of diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kasia J Lipska, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alpha-glucosidase inhibitors lower blood glucose by modifying the intestinal absorption of carbohydrates. The glycemic efficacy, adverse effects, and dosing of alpha-glucosidase inhibitors will be discussed here. Other oral hypoglycemic drugs are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H1288931445"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Although alpha-glucosidase inhibitors have been studied as monotherapy for initial treatment of diabetes and as part of a combination regimen, we do not consider them to be usual first-line therapy, because of relatively low efficacy and poor tolerance. They may play a role as part of a combination regimen in people who consume high-carbohydrate diets and have high postprandial glucose levels, as long as the gastrointestinal side effects are tolerated.</p><p>The alpha-glucosidase inhibitors (<a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a>, <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a>, voglibose) have been studied extensively in Europe and Japan; two of them, acarbose and miglitol, are available in the United States. Taken orally, they inhibit the upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent fashion. These drugs therefore slow the absorption of dietary carbohydrate; the slower rise in postprandial blood glucose concentrations is potentially beneficial in both type 1 and type 2 diabetes. In addition, the transfer of polysaccharides to the more distal small intestine increases the secretion of glucagon-like peptide 1 (GLP-1) and several other gut hormones [<a href="#rid1">1</a>]. In older patients with type 2 diabetes, acarbose may also increase insulin sensitivity [<a href="#rid2">2</a>], although this may have been a nonspecific effect associated with improved glycemia. Alpha-glucosidase inhibitors do not cause hypoglycemia when used as monotherapy or with other agents that do not cause hypoglycemia.</p><p><a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">Acarbose</a> and voglibose have also been evaluated for the prevention of type 2 diabetes. (See  <a class="medical medical_review" href="/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus", section on 'Drugs not recommended for prevention'</a>.)</p><p class="headingAnchor" id="H576724555"><span class="h1">CLINICAL OUTCOMES</span></p><p class="headingAnchor" id="H4011007097"><span class="h2">Glycemic efficacy</span><span class="headingEndMark"> — </span>Several trials have demonstrated the glycemic efficacy of alpha-glucosidase inhibitors in patients with type 2 diabetes [<a href="#rid3">3-8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 41 trials of alpha-glucosidase inhibitor therapy (<a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> 30 trials, <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a> 7, voglibose 1), alpha-glucosidase inhibitors reduced glycated hemoglobin (A1C) more than placebo (mean difference -0.77 and -0.68 percentage points for acarbose and miglitol, respectively) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate meta-analysis involving nine major classes of glucose-lowering therapies (301 trials), monotherapy with alpha-glucosidase inhibitors was associated with a lower A1C than placebo (standardized mean difference [SMD] -0.66) but higher A1C compared with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> (SMD 0.35) [<a href="#rid10">10</a>].</p><p></p><p>In general, alpha-glucosidase inhibitors have resulted in a relatively greater improvement in A1C values than in fasting blood glucose concentrations, consistent with their predominant effect on postprandial hyperglycemia [<a href="#rid5">5</a>]. In a meta-analysis of studies evaluating <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> and <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a>, these agents reduced mean postprandial glucose concentration by approximately 27 mg/dL (1.5 mmol/L) [<a href="#rid11">11</a>]. Some studies suggest that alpha-glucosidase inhibitors are more effective in reducing A1C in people consuming an East Asian diet compared with Western-type diet [<a href="#rid12">12,13</a>].</p><p>Alpha-glucosidase inhibitors are effective when combined with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> [<a href="#rid14">14,15</a>], sulfonylureas [<a href="#rid16">16,17</a>], dipeptidyl peptidase 4 (DPP-4) inhibitors [<a href="#rid18">18-20</a>], insulin [<a href="#rid21">21</a>], or glucagon-like peptide 1 (GLP-1) receptor agonists [<a href="#rid22">22</a>]. However, in the meta-analysis involving major classes of glucose-lowering therapies [<a href="#rid10">10</a>], when added to metformin, alpha-glucosidase inhibitors were associated with a higher odds of treatment failure compared with sulfonylureas. When added as part of triple therapy to metformin and sulfonylurea, alpha-glucosidase inhibitors were associated with higher A1C levels compared with addition of thiazolidinediones, GLP-1 receptor agonists, or basal insulin [<a href="#rid10">10</a>]. In head-to-head comparisons of <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> versus <a class="drug drug_general" data-topicid="9534" href="/d/drug information/9534.html" rel="external">saxagliptin</a> or <a class="drug drug_general" data-topicid="87804" href="/d/drug information/87804.html" rel="external">alogliptin</a>, change in A1C did not differ significantly between the two arms, but treatment with DPP-4 inhibitors was better tolerated [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H2778128030"><span class="h2">Cardiovascular effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular events</strong> – Alpha-glucosidase inhibitors do not appear to increase the risk of adverse cardiovascular events, and some data suggest a possible reduction in risk of myocardial infarction [<a href="#rid25">25</a>]. In a propensity score-matched cohort study from Taiwan evaluating the addition of <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> or a sulfonylurea to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> in people with type 2 diabetes, use of acarbose was associated with a lower risk of major atherosclerotic events (5.9 versus 7.1 events per 1000 person-years, hazard ratio [HR] 0.69, 95% CI 0.52-0.91) compared with sulfonylurea [<a href="#rid26">26</a>]. In the meta-analysis above, alpha-glucosidase inhibitors were not significantly associated with the risk of myocardial infarction or cardiovascular mortality, but there were few events in the available studies [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">Two trials in patients with impaired glucose tolerance report conflicting results:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> appeared to reduce the risk of a composite cardiovascular disease outcome in patients with impaired glucose tolerance. In this trial, 1429 patients with impaired glucose tolerance were randomly assigned to acarbose (100 mg three times daily or placebo for a mean of 3.3 years) [<a href="#rid27">27</a>]. An a priori secondary objective of the study (primarily designed to evaluate the incidence of diabetes) was to evaluate the development of major cardiovascular events or hypertension. Acarbose therapy significantly reduced the risk of cardiovascular events compared with placebo (absolute risk reduction 2.5 percent; HR 0.51, 95% CI 0.28-0.95). This was an unanticipated finding. The major reduction was in myocardial infarction (one event in the acarbose group versus 12 in the placebo group, HR 0.09, 95% CI 0.01-0.72). In addition, there was a reduction in risk of developing hypertension (11 versus 17 percent, absolute risk reduction 5.3 percent, HR 0.66, 95% CI 0.49-0.89). Methodologic flaws (including selection bias, inadequate blinding, and bias in analysis and reporting) have been suggested and reduce our confidence in these findings [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subsequent <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">Acarbose</a> Cardiovascular Evaluation (ACE) trial, designed to compare acarbose with placebo in 6522 Chinese patients with established coronary heart disease and impaired glucose tolerance, the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospital admission for unstable angina, hospital admission for heart failure) occurred in a similar proportion of patients in each group (14 and 15 percent, HR 0.98, 95% CI 0.86-1.11) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk factors</strong> – Data on the effects of alpha-glucosidase inhibitors on serum lipids are conflicting. As an example, in a study of 96 patients with type 2 diabetes, those treated with <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> (100 mg three times daily) for 24 weeks had a 27 percent decrease in the ratio of serum low-density lipoprotein (LDL) cholesterol to high-density lipoprotein (HDL) cholesterol, due to both a decrease in serum LDL cholesterol concentrations (158 to 123 mg/dL [4.1 to 3.2 mmol/L]) and an increase in serum HDL cholesterol concentrations (55 to 64 mg/dL [1.4 to 1.6 mmol/L]) [<a href="#rid30">30</a>]. By comparison, patients treated with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> had no change, while those receiving placebo had a 14 percent increase in the serum LDL/HDL ratio.</p><p></p><p class="bulletIndent1">In the meta-analysis noted above [<a href="#rid9">9</a>], however, no beneficial effects on lipids were seen.</p><p></p><p class="headingAnchor" id="H295574566"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>In short-term trials evaluating alpha-glucosidase inhibitors, there was either no change in weight [<a href="#rid5">5</a>] or mild weight loss (<a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> -0.4 kg, <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a> -0.7 kg) [<a href="#rid31">31</a>]. In a network meta-analysis, acarbose was associated with greater weight loss compared with DPP-4 inhibitors (mean difference -1.2 kg) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H6"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The main side effects of these drugs are flatulence (which affected 73 percent of patients versus 39 percent in the placebo group in one of the above studies [<a href="#rid4">4</a>]) and diarrhea. These symptoms are usually mild, but they may reduce compliance [<a href="#rid5">5</a>]. In one prospective study of 893 patients in Canada treated with <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a>, only 16 to 20 percent were still taking the drug after one year [<a href="#rid33">33</a>]. Slow increases in dose minimize these adverse effects.</p><p>High serum aminotransferase concentrations have been reported with <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> [<a href="#rid34">34-36</a>]. In a meta-analysis of 14 trials, alpha-glucosidase inhibitors were associated with a higher odds of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations of more than threefold above the upper limit of normal (odds ratio [OR] 6.9, 95% CI 2.5-18.8 and OR 6.5, 95% CI 2.4-17.5, respectively) [<a href="#rid37">37</a>]. However, no clinically important adverse events were reported. It is unclear if this is a toxic or hypersensitivity-related reaction.</p><p>In one of the meta-analyses described above, <a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a> doses greater than 50 mg three times daily provided no additional glycemic benefit but were associated with more side effects [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H7"><span class="h1">DOSING</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">Acarbose</a> is available as 50 and 100 mg tablets and should be taken with the first bite of each meal. We begin with 50 mg three times daily. Flatulence, diarrhea, and abdominal discomfort are dose related and almost always resolve if the dose is decreased. Few people tolerate more than 300 mg daily.</p><p><a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">Miglitol</a> is available as tablets. The initial dose is 25 mg three times daily, taken at the start of each meal. After one to two months, if tolerated, the dose may be increased to 50 mg three times daily.</p><p class="headingAnchor" id="H3141679542"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – Although alpha-glucosidase inhibitors have been studied as monotherapy for initial treatment of diabetes and as part of a combination regimen, we do not consider them to be usual first-line therapy, because of modest efficacy and poor tolerance. They may play a role as part of a combination regimen in people who consume high-carbohydrate diets and have high postprandial glucose levels, as long as the gastrointestinal side effects are tolerated. (See <a class="local">'General approach'</a> above and  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Medications not usually recommended'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Alpha-glucosidase inhibitors (<a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a>, <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a>, voglibose) inhibit the upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides and thereby slow absorption of glucose and reduce postprandial blood glucose concentration. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic efficacy</strong> – Alpha-glucosidase inhibitors are less potent than sulfonylureas or <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, lowering glycated hemoglobin (A1C) by only 0.4 to 0.9 percentage points. (See <a class="local">'Clinical outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular effects</strong> – Alpha-glucosidase inhibitors do not appear to increase risk of adverse cardiovascular events, and some data suggest a possible reduction in risk of myocardial infarction. (See <a class="local">'Clinical outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal adverse effects</strong> – The main side effects of alpha-glucosidase inhibitors, which may limit their acceptance, are flatulence and diarrhea. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H3999669865"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David K McCulloch, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dalsgaard NB, Gasbjerg LS, Hansen LS, et al. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. Eur J Endocrinol 2021; 184:383.</a></li><li><a class="nounderline abstract_t">Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23:1162.</a></li><li><a class="nounderline abstract_t">Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17:561.</a></li><li><a class="nounderline abstract_t">Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121:928.</a></li><li><a class="nounderline abstract_t">Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22:960.</a></li><li><a class="nounderline abstract_t">Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83:1515.</a></li><li><a class="nounderline abstract_t">Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998; 21:409.</a></li><li><a class="nounderline abstract_t">Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998; 21:416.</a></li><li><a class="nounderline abstract_t">van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28:154.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA 2016; 316:313.</a></li><li><a class="nounderline abstract_t">Alssema M, Ruijgrok C, Blaak EE, et al. Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis. Nutr Diabetes 2021; 11:11.</a></li><li><a class="nounderline abstract_t">Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther 2013; 35:880.</a></li><li><a class="nounderline abstract_t">Weng J, Soegondo S, Schnell O, et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes Metab Res Rev 2015; 31:155.</a></li><li><a class="nounderline abstract_t">Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24:989.</a></li><li><a class="nounderline abstract_t">Joshi SR, Ramachandran A, Chadha M, et al. Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes. Expert Opin Pharmacother 2014; 15:1611.</a></li><li><a class="nounderline abstract_t">Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab 2002; 15:143.</a></li><li><a class="nounderline abstract_t">Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17:179.</a></li><li><a class="nounderline abstract_t">Takahara M, Shiraiwa T, Katakami N, et al. Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocr J 2014; 61:447.</a></li><li><a class="nounderline abstract_t">Yang HK, Lee SH, Shin J, et al. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Metab J 2019; 43:287.</a></li><li><a class="nounderline abstract_t">Chen X, Jiang H, Li H, et al. Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS). Diabetes Obes Metab 2023; 25:272.</a></li><li><a class="nounderline abstract_t">Schnell O, Mertes G, Standl E, Acarbose-Insulin Combination Study Group. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007; 9:853.</a></li><li><a class="nounderline abstract_t">Wang W, Yan X, Cheng Z, et al. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 2023; 25:3690.</a></li><li><a class="nounderline abstract_t">Du J, Liang L, Fang H, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes Obes Metab 2017; 19:1513.</a></li><li><a class="nounderline abstract_t">Gao B, Gao W, Wan H, et al. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC). Diabetes Obes Metab 2022; 24:991.</a></li><li><a class="nounderline abstract_t">Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25:10.</a></li><li><a class="nounderline abstract_t">Hsu PF, Sung SH, Cheng HM, et al. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. J Clin Endocrinol Metab 2018; 103:3611.</a></li><li><a class="nounderline abstract_t">Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486.</a></li><li><a class="nounderline abstract_t">Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 2004; 47:575.</a></li><li><a class="nounderline abstract_t">Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5:877.</a></li><li><a class="nounderline abstract_t">Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103:483.</a></li><li><a class="nounderline abstract_t">Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100:363.</a></li><li><a class="nounderline abstract_t">Zhang F, Xu S, Tang L, et al. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne) 2020; 11:288.</a></li><li><a class="nounderline abstract_t">Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med 2001; 161:1106.</a></li><li><a class="nounderline abstract_t">Andrade RJ, Lucena MI, Rodríguez-Mendizábal M. Hepatic injury caused by acarbose. Ann Intern Med 1996; 124:931.</a></li><li><a class="nounderline abstract_t">Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe hepatotoxicity. Lancet 1997; 349:698.</a></li><li><a class="nounderline abstract_t">Fujimoto Y, Ohhira M, Miyokawa N, et al. Acarbose-induced hepatic injury. Lancet 1998; 351:340.</a></li><li><a class="nounderline abstract_t">Zhang L, Chen Q, Li L, et al. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2016; 6:32649.</a></li></ol></div><div id="topicVersionRevision">Topic 1787 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449919" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10937515" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of acarbose on insulin sensitivity in elderly patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082525" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734015" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372249" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589648" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540024" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616251" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434443" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33658478" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602502" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25044702" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11375358" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24963542" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173728" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810240" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24561488" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30604599" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36099069" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924867" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37732487" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296055" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35112779" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14683737" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113697" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876091" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727025" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28917545" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428831" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590213" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32582019" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11322845" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of persistence of use of the novel antidiabetic agent acarbose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610937" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatic injury caused by acarbose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078205" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acarbose-induced acute severe hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652620" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acarbose-induced hepatic injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27596383" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
